Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06418711 · ClinicalTrials.gov registry record · Phase 3
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
A Phase 3 study, sponsored by Mannkind Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
NCT06418711 is a Phase 3 study that was terminated before completion, run by Mannkind Corporation. The registered enrollment target is 132 participants.
The verdict
NCT06418711, a Phase 3 study, was terminated before completion, sponsored by Mannkind Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
Study Summary
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
Interventions
- DRUG Placebo
- DRUG Clofazimine Inhalation Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2025-11-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06418711
The ClinicalTrials.gov registry entry for NCT06418711 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06418711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06418711 about?
NCT06418711 is a clinical study titled "ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension". This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
What is the current status of trial NCT06418711?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2024-09-11. Estimated completion is 2025-11-10.
What interventions are being tested in trial NCT06418711?
The interventions under investigation include: Placebo (DRUG), Clofazimine Inhalation Suspension (DRUG).
Who is sponsoring clinical trial NCT06418711?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.